The ability to develop tissue constructs with matrix composition and biomechanical properties that promote rapid tissue repair or regeneration remains an enduring challenge in musculoskeletal engineering. Current approaches require extensive cell manipulation ex vivo, using exogenous growth factors to drive tissue-specific differentiation, matrix accumulation, and mechanical properties, thus limiting their potential clinical utility. The ability to induce and maintain differentiation of stem cells in situ could bypass these steps and enhance the success of engineering approaches for tissue regeneration. The goal of this study was to generate a self-contained bioactive scaffold capable of mediating stem cell differentiation and formation of a cartilaginous extracellular matrix (ECM) using a lentivirus-based method. We first showed that poly-L-lysine could immobilize lentivirus to poly(e-caprolactone) films and facilitate human mesenchymal stem cell (hMSC) transduction. We then demonstrated that scaffoldmediated gene delivery of transforming growth factor β3 (TGF-β3), using a 3D woven poly(e-caprolactone) scaffold, induced robust cartilaginous ECM formation by hMSCs. Chondrogenesis induced by scaffold-mediated gene delivery was as effective as traditional differentiation protocols involving medium supplementation with TGF-β3, as assessed by gene expression, biochemical, and biomechanical analyses. Using lentiviral vectors immobilized on a biomechanically functional scaffold, we have developed a system to achieve sustained transgene expression and ECM formation by hMSCs. This method opens new avenues in the development of bioactive implants that circumvent the need for ex vivo tissue generation by enabling the long-term goal of in situ tissue engineering.
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biomaterials | regenerative medicine | genetic engineering | gene therapy | chondrocyte T he development of tissue constructs with matrix composition and biomechanical properties suitable for tissue replacement remains a significant goal of musculoskeletal tissue engineering. The canonical paradigm for engineering biological tissue substitutes generally involves three critical components (1, 2): (i) cells capable of populating the tissue substitute and generating appropriate neotissue constituents (3); (ii) biomimetic scaffolds that cells can infiltrate and that can support extracellular matrix (ECM) accumulation and organization (4); and (iii) environmental signals such as growth factors (5), small molecules, or physical factors (6) that can direct cell differentiation toward the appropriate lineage of choice. In traditional tissue engineering approaches, these elements are generally applied ex vivo to induce tissue-specific lineage commitment and matrix formation. Although promising strategies for developing bone, cartilage, tendon, and muscle tissue substitutes based on this paradigm exist (7) (8) (9) , these approaches require extensive in vitro manipulation of engineered replacements. Furthermore, upon implantation in vivo, the ability to further specify or modify cell fate is lost.
The ability to induce stem cell differentiation in situ in the absence of exogenous growth factors could significantly enhance tissue regeneration efforts by eliminating the need for in vitro culture of tissue replacements. Patient-derived cells could be harvested and seeded onto scaffolds in a single surgery, or progenitor cells may populate the scaffold in vivo following implantation. This approach requires a biomaterial that can provide functional tissue properties while neotissue is formed in response to persistent cues that guide in situ ECM development. In this regard, previous approaches have developed engineered constructs that elute small molecules or locally deliver proteins capable of initiating cell differentiation (10) or migration (11) . Furthermore, efforts to enhance cell differentiation have involved functionalization of synthetic scaffolds with ECM proteins or peptides recognized by cell surface receptors (12) (13) (14) . More recently, techniques for incorporating gene vectors, such as naked plasmid DNA or nonintegrating adenoviruses and adeno-associated viruses, into tissue replacement constructs have been used (15) (16) (17) (18) (19) . These efforts rely on the ability of transient signals, limited by protein half-life or loss of transgene expression from nonintegrating vectors, to direct cell lineage commitment and drive ECM deposition. Moreover, whereas many of the substrates used in these studies enable localized gene delivery, the mechanical properties do not recapitulate those of native tissues. Thus, implantation of such constructs must be delayed until after ex vivo development of neotissue to allow the implant to function in the context of normal physiological loads.
The goal of this study was to develop a bioactive scaffold capable of mediating cell differentiation and formation of an ECM suitable for replacement of musculoskeletal tissues with mechanical properties that mimic those of native tissues. Lentiviral vectors were Significance Engineered replacements for musculoskeletal tissues generally require extensive ex vivo manipulation of stem cells to achieve controlled differentiation and phenotypic stability. The ability to control cell differentiation using cell-instructive scaffolds that have biomechanical properties approximating those of native tissue would represent a transformative advance in functional tissue engineering. The goal of this study was to develop a bioactive scaffold capable of mediating cell differentiation and formation of an extracellular matrix with the biochemical composition and mechanical features that mimic native tissue properties. By combining innovative gene delivery strategies with advanced biomaterial design, we demonstrate the feasibility of generating constructs capable of restoring biological and mechanical function.
used due to their capacity to efficiently transduce target cells and induce sustained expression of transgenes relevant to cell differentiation and ECM formation in the context of cartilage tissue engineering. Moreover, as poly-L-lysine (PLL)-coated biomaterials effectively immobilize other enveloped viruses and facilitate efficient transduction of cells (20) , PLL was used to functionalize poly (e-caprolactone) (PCL)-derived biomaterials with lentivirus (LV). In this study, we first tested whether PLL could effectively immobilize LV to PCL films and lead to efficient transduction of human mesenchymal stem cells (hMSCs). We then tested whether scaffold-mediated gene delivery with a biomechanically relevant, 3D orthogonally woven PCL scaffold could influence ECM formation by hMSCs in chondrogenic cultures.
Results

LV Immobilized to PLL-Coated PCL Films Efficiently Transduces MSCs.
The feasibility of LV immobilization on a 3D woven PCL scaffold was first tested on 2D PCL films. The goal was to immobilize a LV driving expression of eGFP (LVG) onto the PCL films and to assess transduction efficiency. Films were incubated in a solution of PLL (0.002%) followed by incubation in LVG. Human MSCs were cultured for 3 or 5 days on the films before harvest for flow cytometry. PLL treatment of the PCL facilitated highly efficient cellular transduction, as 93.95 ± 2.28% of the cells were eGFP + (Fig. 1A) . In the absence of PLL, fewer than 1% of cells were eGFP + , indicating that PLL treatment of PCL was necessary and sufficient for mediating the biomaterial-lentivirus interactions and subsequent transduction of hMSCs.
LV Immobilization Enables Scaffold-Mediated Transduction. Based on the proof-of-principle from the 2D film model, this approach was extended to test the effects of LV immobilization on a highly structured, woven PCL scaffold (Fig. 1B) . Cylindrically shaped scaffolds [6 mm diameter (ø) and 700 μm thick] were soaked in 0.002% PLL solution overnight. The PLL adsorbed to the PCL scaffold and did not significantly alter the surface topography or hydrophobicity of the scaffold (Fig. S1 A-D) . Concentrated LVG supernatant was pipetted onto the scaffold and incubated for 1 h before seeding 500,000 hMSCs uniformly onto each of the scaffolds. After 2 wk in culture, cells were isolated using a pronase/collagenase digestion procedure. Flow cytometry showed that 81.60 ± 4.36% of cells were eGFP + ( Fig. 1 C and D) .
Scaffold-Mediated Transduction Results in Cartilage-Specific Matrix Accumulation. We postulated that scaffold-mediated transduction of LV delivering the appropriate transgene could modulate hMSC differentiation and extracellular matrix deposition. To test this hypothesis, LV driving the expression of transforming growth factor β3 (TGF-β3) (LVT) under the control of a constitutive EF-1α promoter was generated ( Fig. 2A) . Early experiments showed that TGF-β3 induced chondrogenesis in this system, whereas other potential transgenes (e.g., BMP-7, SOX9) were less effective at initiating chondrogenic differentiation of hMSCs (Fig. S2 ). The dsRed fluorescent protein was cotranscriptionally expressed via an internal ribosomal entry site from the same vector. In initial studies, cells were either pretransduced in monolayer with TGF-β3-carrying LV (pLVT) before seeding onto the 3D woven PCL scaffold or the scaffold-mediated transduction technique was used to generate bioactive scaffolds with immobilized TGF-β3 LV (iLVT). Either method resulted in production of TGF-β3 at concentrations greater than 17 ng/mL (measured via ELISA) from 1 to 3 wks after seeding scaffolds (Fig. 2B ), whereas constructs comprised of nontransduced (NT) cells produced less than 120 pg/mL. Quantification of sulfated glycosaminoglycan (sGAG) content via the dimethylmethylene blue (DMMB) assay confirmed the hypothesis that the pLVT and iLVT treatments resulted in similar chondrogenic induction after 2 wks ( Fig. 2C ; pLVT, 12.96 μg sGAG/μg DNA vs. iLVT, 12.87 μg sGAG/μg DNA, P = 0.95), whereas NT constructs did not produce significant levels of sGAG (3.76 μg sGAG/μg DNA, P < 0.0002 vs. pLVT and iLVT). There was no sGAG detectable by Safranin-O staining of constructs composed of nontransduced cells (Fig. 2D) , whereas moderate to extensive sGAG deposition throughout the pores of the woven PCL scaffold was observed in the pLVT and iLVT groups ( Fig. 2 E and F). Furthermore, fluorescence microscopy of hMSCs overexpressing TGF-β3 and dsRed demonstrated that iLVT-transduced cells adopted a spherical morphology, a phenotypic characteristic of chondrocytes (Fig. 2I) . Fluorescence was not observed in nontransduced cells (Fig. 2G) , and cells engineered with GFP alone (iLVG) retained an elongated, fibroblast-like morphology (Fig. 2H) .
We next compared the chondrogenesis induced by scaffoldmediated transduction to that induced by supplementation of medium with recombinant human TGF-β3 (rhTGF-β3). Constructs were induced to differentiate via iLVT transduction or addition of TGF-β3 to medium and were then cultured with halfmedium changes every 3 days. Scaffold-mediated transduction resulted in overexpression of TGF-β3, measured by quantitative RT-PCR (qRT-PCR) at days 14 and 28 (D14 and D28) after chondrogenic induction ( Fig. 3A ; 397-and 560-fold over nontransduced controls, respectively). Total TGF-β3 levels in culture medium for iLVT-transduced constructs ranged from 9.6 ng/mL to 21 ng/mL. Although the majority of the protein was bound in the latent form, 1.1-1.8 ng/mL of free TGF-β3 was detected over the course of the study (Fig. 3 B and C) .
Chondrogenic differentiation induced by scaffold-mediated transduction was further examined by comparing the gene expression profile of constructs from each group. Quantitative RT-PCR showed an up-regulation of aggrecan (ACAN) and the α1 chain of type II collagen (COL2A1), two markers of chondrogenic differentiation, in both the iLVT and the rhTGF-β3 groups compared with control constructs cultured in the absence of TGF-β3 ( Fig. 4 A and B) . ACAN expression levels were comparable between iLVT and rhTGF-β3 groups (P = 0.21), but COL2A1 expression levels were higher in the iLVT group at D14 than in the rhTGF-β3 group (P < 0.02). Gene expression was also measured for the α1 chains of types 1 (COL1A1) and 10 collagen (CO-L10A1), markers of a fibrotic and a hypertrophic phenotype, respectively ( Fig. 5 A and B) . COL1A1 and COL10A1 expression was up-regulated by both iLVT and rhTGF-β3 treatment at D14, with iLVT levels higher than rhTGF-β3 levels (P < 0.05). The expression of COL1A1 decreased to control levels by D28 for both groups, whereas COL10A1 remained elevated in both groups compared with controls. The up-regulation of COL10A1 is consistent with previous reports of hypertrophy in hMSCs undergoing chondrogenic differentiation (6, 21, 22) . At D28, up-regulation of the chondrogenic markers continued and was similar in both groups, indicating comparable levels of stable chondrogenic differentiation after iLVT-mediated differentiation or standard TGF-β3-supplemented differentiation protocols.
Measurements of total collagen and sGAG content demonstrated that the up-regulation of markers of differentiation led to the development of an extracellular matrix consistent with chondrogenesis (Fig. 4 C and D) . Trends comparing the quantity of sGAG normalized to double-stranded DNA (Fig. 4C) were equivalent to those comparing absolute values (Fig. S3) . The rhTGF-β3 and iLVT groups showed comparable levels of sGAG/DNA at D14 (15.36 ± 1.77 μg/μg and 12.90 ± 0.88 μg/μg, respectively, P = 0.21), although the NT group without TGF-β3 showed significantly lower levels (4.67 ± 0.25 μg/μg, P < 0.0002). Sulfated GAG levels increased significantly by D28 (P < 0.00001) in the rhTGF-β3 and iLVT groups, but were not statistically different from one another (35.97 ± 1.97 μg/μg and 36.07 ± 1.79 μg/μg, respectively, P = 0.96). Culture time did not influence sGAG levels in the NT group (P = 0.96), which remained lower than those in the rhTGF-β3 and iLVT groups (P < 0.00001). Similar trends held for total collagen levels normalized to DNA content (Fig. 4D) , although a significant difference at D14 between the rhTGF-β3 and iLVT groups was observed (P = 0.045). The significance of this difference was lost when total collagen content of constructs was not normalized to construct DNA content (P = 0.053, Fig. S2 ).
Histological and immunohistochemical assays supported the gene expression and biochemical evidence of chondrogenic differentiation in both the iLVT and the rhTGF-β3 groups. Safranin-O and type II collagen labeling showed limited ECM accumulation at D14, but extensive assembly of GAG and collagen II ECM constituents was observed throughout the pores of the 3D woven scaffold in the rhTGF-β3 and iLVT groups at D28 (Fig. 4 E-L) . Although type I and type X collagens were detected in D28 samples, they appeared less prominent than either type II collagen or GAG (Fig. 5 C-F) . Limited ECM deposition was observed in the NT group.
Confined compression testing was used to evaluate the mechanical properties of the tissue replacements generated in culture, with the goal of attaining a compressive modulus similar to that of native articular cartilage (23) . The aggregate modulus (H A ) of the scaffolds directly after cell seeding (D0) was 0.26 ± 0.024 MPa. The H A of the cell-seeded constructs was not influenced by the addition of TGF-β3 to culture conditions (Fig. 6A) , as no significant differences were detected among treatments (P > 0.18); however, H A did increase for each group compared with D0 (P < 0.003). The hydraulic permeability (k) was influenced by experimental treatment (Fig. 6B) , with samples in the rhTGF-β3 condition more rapidly approaching values similar to articular cartilage than NT samples (P = 0.013). This difference was not maintained to D28, as values for k were not significantly different in any of the three culture groups. Permeability values decreased in all groups in comparison with D0 samples (P < 0.037).
Discussion
The findings of this study show that scaffold-mediated transduction of hMSCs with lentiviral vectors driving expression of TGF-β3 leads to potent differentiation toward a chondrogenic lineage and accumulation of a cartilage-like ECM. Histological and biochemical measures confirmed the hypothesis that the iLVT treatment induced a chondrocyte-like phenotype, as displayed by hMSCs adopting a spherical morphology and depositing an ECM rich in type II collagen and glycosaminoglycan, major components of articular cartilage. By nearly all measures of gene regulation, protein content, and biomechanical properties, the level of chondrogenic differentiation achieved at D28 by immobilizing LVT was indistinguishable from that using rhTGF-β3. The observed increase in sGAG and collagen content is consistent with previous reports from our group and others when using hMSCs for chondrogenesis (24) (25) (26) .
In these studies, LV was used to drive constitutive overexpression of TGF-β3 to induce chondrogenesis. An extensive body of literature has shown that TGF-β3 is a potent regulator of hMSC differentiation to the chondrogenic lineage (27) (28) (29) (30) (31) (32) . Various other transgenes and gene products, including IGF1, SOX9, and multiple members of the TGF-β superfamily, including TGF-β1, BMP-2, BMP-4, and BMP-7, and combinations thereof, have been used to induce chondrogenesis in progenitor cells (21, (33) (34) (35) (36) (37) (38) (39) . In these studies, the induction of chondrogenesis with viral vectors generally has been performed in the context of monolayer transduction and chondrogenesis in pellet cultures. Although these studies demonstrate the feasibility of virus-based transduction methods to drive MSC differentiation, the ability to transduce cells in situ via scaffold-mediated gene delivery opens new avenues for generating implant-ready, bioactive tissue engineering scaffolds capable of restoring function to a joint immediately upon implantation while also driving the development of a mature, viable tissue replacement using the host as the bioreactor.
Moreover, the results from these studies indicate that the scaffold-mediated transduction technique may provide a means of transducing cells in vivo simply by seeding them intraoperatively onto a cell-instructive, biomechanically functional scaffold that directs cell lineage commitment and ECM development in a controlled and persistent manner. Using this approach would abrogate the need for ex vivo expansion of cells used in tissue engineering as well as the ex vivo conditioning of the maturing tissue substitute by allowing the host's own cells to recapitulate functional tissues after infiltrating an acellular bioactive scaffold. Our findings suggest that scaffold-mediated gene delivery could provide an efficient means of in situ transduction, owing to the ability of PLL to immobilize vectors to the biomaterial, as well as the efficiency of transduction of the VSV-G pseudotyped lentivirus. In addition, we have previously demonstrated that passive adsorption of ECM onto highly cationic surfaces can direct both viral immobilization and cell adhesion (20) , opening the possibility of functionalizing polymeric scaffolds with gene delivery vehicles as well as ECM components or synthetic peptides capable of enhancing cell differentiation and tissue formation (12, 14) . However, important questions, such as whether endogenous cells that infiltrate the scaffold at the site of implantation can be driven to differentiate toward the chondrocyte lineage, remain unanswered.
Our findings extend previous work showing biomaterialmediated gene delivery using viral vectors (20, (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) . The majority of this work demonstrated the ability to specify the spatial location of delivered vectors, rather than the induction of tissuespecific differentiation. An exception to this was the work by Phillips et al., in which fibroblasts seeded on a collagen scaffold containing PLL-immobilized γ-retrovirus were transdifferentiated to the osteogenic lineage (43) . An important advance of the current study was the use of PLL to immobilize gene delivery vectors to a highly structured, 3D woven PCL scaffold. Although other methods, such as 3D printing, electrospinning, and solvent casting/salt leaching are available for fabricating polymer-based scaffolds for cartilage tissue engineering, the orthogonally woven PCL scaffold possesses controlled anisotropic and nonlinear mechanical properties before cell seeding (50, 51) . Although the properties of this 3D woven scaffold have been extensively characterized previously, here we show that PLL treatment does not alter the porosity, surface topography, or hydrophobicity of the scaffold (SI Results). These properties closely mimic the biomechanical features of articular cartilage and would allow for immediate loading upon implantation. This aspect may be crucial to the goal of inducing tissue generation in situ upon implantation of a degradable, bioactive scaffold, because functional restoration of a joint is likely to be facilitated by a biomaterial possessing mechanical properties approximating those of articular cartilage, while also permitting the formation of a viable, cartilage neotissue that could eventually serve as the load-bearing tissue after the complete degradation of the PCL. As demonstrated here, the development of cartilaginous ECM constituents served to enhance (i.e., decrease) the hydraulic permeability of the construct by four orders of magnitude compared with D0 constructs, as pores of the woven scaffold were filled in with neotissue that consolidated the construct. Importantly, however, the aggregate modulus of the tissue engineered constructs was the same order of magnitude as that of native articular cartilage before deposition of ECM, and these properties were maintained throughout the culture period as the compressive properties are dominated by those of the 3D woven scaffold (50) . In contrast, scaffolds composed of collagen, alginate, or fibrin-based hydrogels capable of encapsulating gene delivery vectors possess compressive properties below those of native articular cartilage (52) (53) (54) . In this regard, the 3D woven structure provides several highly desirable properties as a scaffold for biomaterial-mediated gene delivery for in situ tissue engineering.
An important feature of the current study includes the use of self-inactivating lentiviral vectors in place of γ-retrovirus (43), nonintegrating viral vectors (16, (40) (41) (42) 55) , or naked plasmid DNA (15) . Although considerable progress has been made with regard to spatial control of gene delivery to cells, transient gene expression and poor transfection/transduction efficiencies may not allow sufficient control of cell phenotype and tissue development. LV represents an attractive option for efficient and sustained gene delivery, in addition to other advantageous properties including high packaging capacity (>10 kb), low immunogenicity, low cytotoxicity, and broad tropism (56) (57) (58) (59) . The development of self-inactivating vectors has addressed the serious safety concerns of earlier generations of viral systems (60) and made LV an attractive option for clinical use that overcomes the shortcomings of many alternative vector systems.
The use of LV likely explains the efficient transduction of the slowly dividing hMSCs compared with that in other studies involving γ-retroviral vectors. Using LV, an efficiency of scaffoldmediated transduction of roughly 82% was achieved, whereas a previous study of scaffold-mediated gene delivery to fibroblasts with retrovirus showed a transduction efficiency of ≥20% (43). Therefore, biomaterial-mediated delivery of LV may serve as a promising approach for applications requiring robust and uniform transgene expression, such as those seeking to generate homogeneous tissue formation or those using biomaterials as delivery depots of anti-inflammatory gene products for protection against further degeneration of musculoskeletal tissues.
Although effective at inducing chondrogenesis, the safety of constitutive overexpression of TGF-β3 serves as one of the drawbacks of this study. To circumvent this, future studies may be directed toward the replacement of the constitutive EF-1α promoter with a drug-inducible promoter (61) , which could confer engineered control of the duration and magnitude of transgene expression. Moreover, the technique of biomaterial-mediated gene delivery may be applied toward engineering complex tissues or tissue interfaces for regenerative medicine (62) (63) (64) .
Toward the goal of in situ tissue engineering, it is important to consider the effects of the synovial environment on viral transduction efficiency and the ability to transduce target cells in vivo. Although we did not directly test transduction efficiency in the context of synovial fluid, target cells were transduced in medium containing 10% FBS. Synovial fluid is considered a plasma dialysate, with the major difference between serum and synovial fluid being the abundance of hyaluronic acid in the latter (65) . The presence of synovial fluid does not preclude lentiviral transduction, as previous studies have demonstrated transduction of synovial fibroblasts as well as cells in ligaments, tendons, and joint capsule via direct intra-articular injection of virus to synovial joints (66) (67) (68) . Importantly, we showed that material-mediated transduction of hMSCs remained >90% after rinsing the substrates upon which lentivirus was immobilized. Moreover, we have also shown that incubation of PLL-coated surfaces with retrovirus for 16 h results in high levels of transduction of fibroblasts (∼70%) (20) , suggesting that the half-life of the vector does not preclude efficient transduction. Collectively, these results support the potential of viral transduction in the joint environment.
These studies demonstrate that scaffold-mediated gene delivery may serve as a promising strategy for in situ engineering of musculoskeletal tissues. By coupling the biomechanically relevant woven scaffold to an effective gene delivery vehicle carrying the appropriate transgene, we have demonstrated both the proofof-principle of scaffold-mediated delivery to hMSCs and the potential utility of this method for tissue engineering of articular cartilage. In this work, a relatively inert material such as PCL was functionalized with the ability to specify cell differentiation and ECM production. As such, this technique for LV immobilization can be applied in the context of other PCL-based scaffolds and potentially using other materials than PCL. More importantly, it is possible that our approach to scaffold-mediated transduction could be extended to a variety of applications using numerous other cell types, transgenes, and drug-inducible promoters (69) . When combined with the appropriate scaffold structure and material, we envision broad utility of this technique in the area of recapitulating the complex organization of heterogeneous tissues, such as osteochondral tissues, and in the delivery of therapeutic transgenes capable of mediating protection and repair of tissues in the context of a diseased or damaged joint.
Methods
Human Mesenchymal Stem Cell Isolation and Expansion. Bone marrow was obtained in concordance with an approved Institutional Review Board exemption as discarded and de-identified waste tissue from adult bone marrow transplant donors at Duke University Medical Center. Adherent cells were expanded in DMEM-low glucose (Gibco) supplemented with L-glutamine, sodium pyruvate, 1 ng/mL basic fibroblast growth factor (Roche), penicillin/streptomycin (Gibco), and 10% lot-selected FBS (HyClone). Isolated cells from three donors were combined in equal numbers in a superlot after passage two and used as described below.
Lentivirus Production. All plasmids used in the production of LV were obtained via the Addgene Plasmid Repository. The cDNA for TGF-β3 was obtained from HEK-293T cells via RT-PCR and cloned into a lentiviral transfer vector [Addgene Plasmid 12250 (70) modified with a custom multiple-cloning site downstream of the EF-1α promoter]. Virus driving overexpression of eGFP was produced using either Addgene Plasmid 21320 (71) or 11645 (72) modified to contain an EF1-α-eGFP cassette. To produce VSV-G pseudotyped LV, 4.2e6 HEK-293T cells were plated onto each 10-cm dish in DMEM-high glucose supplemented with L-glutamine, sodium pyruvate, and 10% FBS (D-10 medium) . The following day, cells on each dish were cotransfected with the appropriate lentiviral transfer plasmid (20 μg), the second-generation packaging plasmid, psPAX2 (Addgene 12260, 15 μg), and the pMD2.G (Addgene 12259, 6 μg) envelope plasmid via calcium phosphate precipitation (73) . After an overnight incubation, transfection medium was removed and replaced with 12 mL of fresh 293T medium. Conditioned medium containing LV was collected at 36 h and 60 h posttransfection. The raw lentiviral supernatant was cleared of producer cells via centrifugation and subsequent filtration through 0.45-μm cellulose acetate filters, snap frozen, and stored at −80°C until future use.
Polycaprolactone Film Production and LV Immobilization. PCL (molecular weight 70,000-90,000; Sigma-Aldrich) was dissolved in glacial acetic acid at a 10% wt/vol ratio as in ref. 40 . PCL solution was pipetted into a well plate, and the acid was allowed to evaporate overnight. Films were quenched with 1 N NaOH, washed in DPBS, and aseptically processed through an ethanol gradient in preparation for cell culture experiments. Films were then incubated in PLL solution (Sigma-Aldrich) diluted to 0.002% with DPBS for 1 h to allow for passive adsorption. PLL was aspirated, and LV-eGFP supernatant was pipetted into the well plate and allowed to incubate for 4 h at 37°C (20) . DPBS was used in place of PLL in untreated control wells. After LV immobilization, viral supernatant was aspirated, the wells were rinsed with DPBS, and then human MSCs at passages 4-6 were plated in wells at a density of 5,000/cm 2 or 10,000/cm 2 and cultured for an additional 3-5 days. Cells were trypsinized, washed with DPBS, and fixed with 1% paraformaldehyde (PFA) before flow cytometry. A total of two experiments were performed with n = 2-3 wells per group per experiment. Data presented are from the average of all experiments.
Scaffold-Mediated Transduction and Chondrogenic Differentiation. Threedimensional woven PCL scaffolds were produced as previously described (50, 51) . The orthogonally woven scaffold contained three warp and four weft layers interlocked by a third set of fibers passing through the thickness of the structure. Scaffold pore sizes ranged from 100 μm to 300 μm, with a pore fraction volume of ∼50%, which was not altered by PLL treatment (Fig. S3C) . Cylindrical samples (6 mm ø) were punched from the scaffold material, treated with 1 N NaOH to increase wettability, rinsed in water, and aseptically processed through an ethanol gradient for tissue culture experiments. Sterilized scaffolds were soaked overnight in 0.002% PLL before viral immobilization and cell seeding. Atomic force microscopy (74), contact angle measurements (75) , and microcomputed tomography (76) were performed as described in SI Methods to compare PLL-treated scaffolds to control PBSsoaked scaffolds to determine the effect of the PLL coating on the original scaffold properties, which have been extensively characterized previously.
Before transduction, conditioned 293T medium containing LV was concentrated roughly 50-fold in a 100-kDa molecular mass cutoff filter (Millipore). In the pretransduced LVT group, passage 4 hMSCs were cultured overnight in 12 mL hMSC expansion medium supplemented with 300 μL of concentrated LV and 4 μg/mL polybrene (Sigma-Aldrich). Transduction medium was then exchanged for fresh expansion medium until the end of the passage and scaffold seeding as described below.
Scaffolds were transferred from PLL-containing wells to low-attachment well plates (Corning), and 50 μL of concentrated LV was pipetted onto each scaffold in the iLVT group. Control scaffolds were treated with 50 μL of fresh D-10 medium. Scaffolds were incubated at room temperature for 1 h. Passage 4 hMSCs were trypsinized, counted, and resuspended at a density of 25e6/mL. Each scaffold received 20 μL of the cell suspension, and the resultant constructs were incubated for 1 h in a humidified incubator at 37°C for 1 h before the addition of 1 mL of hMSC expansion medium. Fresh medium was exchanged 3 days later. Six days after seeding, constructs were induced to differentiate by changing the medium to serum-free, DMEMhigh glucose (Gibco) supplemented with ITS + (BD), penicillin/streptomycin (Gibco), dexamethasone (100 nM), ascorbic acid (50 μg/mL), and L-proline (40 μg/mL) and, in the rhTGF-β3 group only, 10 ng/mL rhTGF-β3 (R&D Systems). A half medium change occurred every 3 days for all groups until samples were harvested at 14 days or 28 days after inducing chondrogenic differentiation. An aliquot of medium was collected from four samples during culture and used for an ELISA (R&D Systems) to measure TGF-β3 concentrations per the manufacturer's instructions.
Biochemical and Biomechanical Assays. Samples used for biochemical and biomechanical analyses were harvested, rinsed with DPBS, and stored at −20°C until testing. Test specimens were obtained by taking a 3-mm ø biopsy punch from constructs. The biopsy was used for mechanical testing whereas the annulus was lyophilized and then digested in 125 μg/mL papain at 60°C overnight for biochemical analysis, using the picogreen assay (Invitrogen) to measure double-stranded DNA, the ortho-hydroxyproline assay (77) for measuring total collagen content, and the dimethylmethylene blue assay (78) for measuring the total sulfated glycosaminoglycan content of constructs (n = 6 per group).
Aggregate modulus and hydraulic permeability were determined via confined compression testing, using a Bose ELF 3200 materials testing system. Specimens (n = 4 per group) were subjected to a 10-gF tare load and a 30-gF step compressive load until equilibration. To calculate H A and k, creep data were fitted to a three-parameter, nonlinear least-squares regression fit based on the biphasic, viscoelastic model describing articular cartilage (23) .
Gene Expression Analysis. Samples for gene expression analysis were harvested, rinsed in DPBS, and snap frozen until further processing. Total RNA was isolated per manufacturer's recommendations, using TRIzol (Invitrogen), following tissue homogenization with a biopulverizer chilled in liquid nitrogen. Reverse transcription was performed using the superscript VILO cDNA synthesis kit (Invitrogen) per manufacturer's instructions. Quantitative RT-PCR was performed with n = 4 samples per group on a StepOnePlus, using Power Sybr (Applied Biosystems) per manufacturer's instructions. Gene expression was probed using the following primer pairs designed to contain intervening introns to avoid aberrant genomic DNA amplification: ACAN [forward (F), 5′-CACTTCTGAGTTCGTGGAGG-3′; reverse (R), 5′-ACTGGACT-CAAAAAGCTGGG-3′]; COL1A1 (F, 5′-TGTTCAGCTTTGTGGACCTC-3′; R, 5′-TTCTGTACGCAGGTGATTGG-3′); COL2A1 (F, 5′-GGCAATAGCAGGTTCACGTA-3′; R, 5′-CTCGATAACAGTCTTGCCCC-3′); COL10A1 (F, 5′-CATAAAAGGCCC-ACTACCCAAC-3′; R, 5′-ACCTTGCTCTCCTCTTACTGC-3′); and TGFB3 (F, 5′-GGAAAACACCGAGTCGGAATAC-3′; R, 5′-GCGGAAAACCTTGGAGGTAAT-3′). Ribosomal 18s (F, 5′-CGGCTACCACATCCAAGGAA-3′; R, 5′-GGGCCTCGAAA-GAGTCCTGT-3′) was used as a reference gene for normalization. All oligonucleotides were synthesized by IDT. Efficiencies for each primer pair were determined and fold changes in expression levels were calculated using the Pfaffl method (79).
Histological and Immunohistochemical Processing. Samples for histology and immunohistochemistry were rinsed in DPBS upon harvest, fixed in 4% paraformaldehyde for 48 h, paraffin embedded, and sectioned at 10 μm thickness. Samples were stained with Safranin-O/fast green/hematoxylin, using standard protocols. For immunohistochemistry, sections were stripped of paraffin using xylenes and hydrated in an ethanol series, and epitopes were retrieved with Digest-All pepsin solution (Invitrogen) before peroxidase quenching. Sections were blocked with goat serum, incubated with a primary antibody (Collagen Type I, mouse monoclonal, Abcam ab90395; Collagen Type II, mouse monoclonal, Developmental Studies Hybridoma Bank, University of Iowa, II-II6B3; Collagen Type X, mouse monoclonal, Sigma C7974) for 1 h at room temperature, incubated with a biotinylated secondary antibody (goat anti-mouse; Abcam ab97021) at room temperature, treated with streptavidin HRP conjugate, developed using AEC, and mounted with VectaMount (Vector Labs). Human osteochondral tissue was used as positive controls and samples incubated without primary antibody were used to confirm staining specificity.
Fluorescence Microscopy. Fluorescence microscopy was performed on a Zeiss S100 Axiovert inverted microscope, and confocal microscopy was performed on a Zeiss LSM 510 laser scanning microscope.
Statistical Analysis. Statistical analysis was performed in the Statistica 7 software package. ELISA data comparing pLVT and iLVT treatments were analyzed using an independent paired t test. Other analyses were performed using ANOVA with Fisher's protected least significance difference post hoc test with α = 0.05. For biomechanical analyses, all treatments were also compared with reference samples harvested 1 h after seeding, using a paired t test with α = 0.05. For qRT-PCR comparisons, fold change values were logtransformed before statistical analysis. Average group values and SEMs were calculated in the logarithmic space before transforming data to linear values for reporting fold changes. In preliminary experiments, the efficacy of various vectors immobilized to the woven scaffold was evaluated. Transforming growth factor β3 (TGF-β3), bone morphogenetic protein-7 (BMP-7), and the transcription factor SOX9 were selected as candidate transgenes for inducing chondrogenic differentiation in our culture system. Lentiviral vectors driving expression of BMP-7 (LVBMP7) and SOX9 (LVSOX9) were produced following the same technique as lentivirus driving the expression of TGF-β3 (LVT). (A-C) Vectors were immobilized to the woven scaffold. Histology and immunohistochemistry from day 14 (D14) and D28 constructs show that immobilized LVT (iLVT) resulted in accumulation of glycosaminoglycan (GAG) (D14 and D28, A and B, respectively) and type II collagen (C), ECM components characteristic of articular cartilage. (E-G) Results resembled those of controls cultured with recombinant human TGF-β3 (rhTGF-β3) supplementation. (D and H) LVBMP-7 and LVSOX9 transduction did not induce chondrogenesis in this culture system, as demonstrated by the absence of positive Safranin-O staining for these samples. As such, future experiments made use of LVT. (Scale bars, 100 μm.) Fig. S3. (A and B) Total sulfated GAG (sGAG) (A) and total collagen content (B) in engineered constructs. Trends pertaining to sGAG/DNA were identical to those obtained when comparing total sGAG per construct. Trends pertaining to total collagen content were identical to those obtained when comparing total collagen/DNA, with the exception of loss of statistical significance between D14 rhTGF-β3 and iLVT samples (P = 0.053).
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